Scancell Holdings plc (AIM: SCLP)

Market Cap	139.44M
Revenue (ttm)	n/a
Net Income (ttm)	-5.86M
Shares Out	929.60M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,260
Open	15.50
Previous Close	15.00
Day's Range	14.45 - 15.50
52-Week Range	8.60 - 19.75
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 24, 2025

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 61
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SCLP